TYRP-1 CAR T cell therapy / UCLA - LARVOL DELTA

CAR-T cell therapy targeting surface expression of TYRP1 to treat cutaneous and rare melanoma subtypes. (PubMed, Nat Commun) - "Furthermore, no systemic or off-tumor severe toxicities are observed in an immunocompetent murine model. The efficacy and safety profile of the TYRP1 CAR-T cell therapy supports the ongoing preparation of a phase I clinical trial."

CAR T-Cell Therapy • IO biomarker • Journal • Eye Cancer • Melanoma • Oncology • Solid Tumor • Uveal Melanoma • Tyrosinase • TYRP1

Engineering a potent T-cell response against solid tumors (AACR 2023) - "The TYRP1 CAR-T cell therapy presents robust antitumor activity without toxicity in murine and patient-derived cutaneous, acral, and uveal melanoma models. Based on the efficacy and safety profile of this therapy, we are currently planning the phase I clinical trial."

IO biomarker • Eye Cancer • Melanoma • Oncology • Solid Tumor • Uveal Melanoma • TYRP1